Chris Packard, Professor of Vascular Biochemistry at the University of Glasgow, UK, highlights the importance of PROMINENT trial data on triglyceride lowering to reduce cardiovascular risk and new insights into the role of ANGPTL3, 4 and 8 proteins and apoCIII in controlling triglyceride-rich lipoproteins levels.
Derick Raal, Head of Lipidology and Endocrinology at Johannesburg Hospital, South Africa, stresses the importance of the PROMINENT trial in showing that triglyceride reduction with pemafibrate did not translate into better cardiovascular (CV) outcomes and looks forward to outcome studies of ANGPTL3 and apoCIII inhibition to establish their CV effects.
Rob Hegele, Jacob J Wolfe Distinguished Medical Research Chair, Robarts Research Institute, Ontario, Canada, highlights progress in genetic testing for hypertriglyceridaemia using gene variants for triglyceride metabolism, and hopes that patient genotyping in hypertriglyceridaemia trials will help predict who is likely to respond to novel therapies.
Anne Goldberg, Professor of Medicine, Washington University School of Medicine, USA, discusses likely reasons for the disappointing PROMINENT trial results and is eager to find out if targeting apoCIII with either antisense oligonucleotide or mRNA silencing approaches may represent a way forward in treating patients with severe chylomicronaemia.
